Objective: To evaluate whether augmented reality microscopy surgical fluorescence technology, already Food and Drug Administration approved for vascular neurosurgery, can aid in lateral skull base surgery during cerebellopontine (CPA) tumor resection and microvascular decompression.
Study Design: Pilot prospective uncontrolled observational cohort study.
Setting: An academic tertiary care hospital.